Last10K.com

Life Technologies Corp (1073431) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2011

Life Technologies Corp

CIK: 1073431

Exhibit 99.1

 

LOGO

Investor and Financial Contacts:

Carol Cox

Investor Relations

760-603-7208

Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results

 

   

Fourth quarter revenue increased 4 percent to $970 million; GAAP earnings per share (EPS) increased to $0.69, or $1.06 on a non-GAAP basis, an increase of 18 percent

 

   

2011 revenue increased 4 percent to $3.7 billion; GAAP EPS increased to $2.23, or $3.73 on a non-GAAP basis, an increase of 5 percent

 

   

2011 free cash flow totaled $710 million

 

   

2012 outlook of non-GAAP organic revenue growth of 2 to 4 percent over 2011; Non-GAAP EPS guidance range of $3.90 to $4.05

CARLSBAD, CA, February 7, 2012

— Life Technologies Corporation (NASDAQ: LIFE) today announced results for the quarter and full year ended December 31, 2011 and provided financial guidance for 2012.

“I am pleased with our performance in the fourth quarter and throughout 2011, even as we faced a number of challenges, including macroeconomic headwinds and constrained spending by some of our customers,” said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies. “Overcoming these obstacles, we delivered top line growth, reduced our operating costs to meet the slower growth environment and expanded our operating margins an impressive 110 basis points, all of which we leveraged to deliver bottom line growth for the twelfth consecutive year. We finished the year with strong free cash flow of $710 million.”

“Looking ahead to 2012, we expect growth in our game-changing Ion Torrent franchise, expansion in end markets and geographies and continued operational efficiencies to drive organic revenue growth of 2 to 4 percent over 2011 results and adjusted non-GAAP EPS in a range of $3.90 to $4.05.”


The following information was filed by Life Technologies Corp on Tuesday, February 7, 2012 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Life Technologies Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Life Technologies Corp.

Continue

Assess how Life Technologies Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Life Technologies Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2012 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Valuation And Qualifying Accounts
Valuation And Qualifying Accounts (details 1)
Valuation And Qualifying Accounts (details)
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity And Comprehensive Income
Business Activity Summary Of Significant Accounting Policies And Significant Accounts
Business Activity Summary Of Significant Accounting Policies And Significant Accounts (details Textual)
Business Activity Summary Of Significant Accounting Policies And Significant Accounts (policies)
Business Activity, Summary Of Significant Accounting Policies And Significant Accounts (details 1)
Business Activity, Summary Of Significant Accounting Policies And Significant Accounts (details 2)
Business Activity, Summary Of Significant Accounting Policies And Significant Accounts (details 3)
Business Activity, Summary Of Significant Accounting Policies And Significant Accounts (details 4)
Business Activity, Summary Of Significant Accounting Policies And Significant Accounts (details 5)
Business Activity, Summary Of Significant Accounting Policies And Significant Accounts (details 6)
Business Activity, Summary Of Significant Accounting Policies And Significant Accounts (details)
Business Activity, Summary Of Significant Accounting Policies And Significant Accounts (tables)
Business Combinations And Divestitures
Business Combinations And Divestitures (details)
Commitments And Contingencies
Commitments And Contingencies (details 1)
Commitments And Contingencies (details Textual)
Commitments And Contingencies (details)
Commitments And Contingencies (tables)
Common Stock And Preferred Stock
Common Stock Preferred Stock And Preferred Stock Purchase Rights Plan (details)
Employee Benefit Plans
Employee Benefit Plans (details 1)
Employee Benefit Plans (details 2)
Employee Benefit Plans (details 3)
Employee Benefit Plans (details 4)
Employee Benefit Plans (details 5)
Employee Benefit Plans (details 6)
Employee Benefit Plans (details 7)
Employee Benefit Plans (details 8)
Employee Benefit Plans (details Textual)
Employee Benefit Plans (details)
Employee Benefit Plans (tables)
Employee Stock Plans
Employee Stock Plans (details 1)
Employee Stock Plans (details 2)
Employee Stock Plans (details 3)
Employee Stock Plans (details 4)
Employee Stock Plans (details Textual)
Employee Stock Plans (details)
Employee Stock Plans (tables)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments (details 1)
Fair Value Of Financial Instruments (details 2)
Fair Value Of Financial Instruments (details 3)
Fair Value Of Financial Instruments (details 4)
Fair Value Of Financial Instruments (details 5)
Fair Value Of Financial Instruments (details Textual)
Fair Value Of Financial Instruments (details)
Fair Value Of Financial Instruments (tables)
Geographic Information
Geographic Information (details)
Geographic Information (tables)
Income Taxes
Income Taxes (details 1)
Income Taxes (details 2)
Income Taxes (details 3)
Income Taxes (details 4)
Income Taxes (details Textual)
Income Taxes (details)
Income Taxes (tables)
Lines Of Credit
Lines Of Credit (details)
Long -term Debt (details 1)
Long -term Debt (details)
Long-term Debt
Long-term Debt (details Textual)
Long-term Debt (tables)
Quarterly Financial Data
Quarterly Financial Data (unaudited) (details)
Quarterly Financial Data (unaudited) (tables)
Subsequent Events
Subsequent Events (details)
Supplemental Cash Flow Information
Supplemental Cash Flow Information (details)
Supplemental Cash Flow Information (tables)
CIK: 1073431
Form Type: 10-K Annual Report
Accession Number: 0001193125-12-089112
Submitted to the SEC: Wed Feb 29 2012 4:08:54 PM EST
Accepted by the SEC: Wed Feb 29 2012
Period: Saturday, December 31, 2011
Industry: Biological Products No Disgnostic Substances

External Resources:
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/1073431/0001193125-12-089112.htm